miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase

BACKGROUND: Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is the most convincing predictive biomarker for temozolomide (TMZ) response in patients with glioblastoma multiforme (GBM). However, technical obstacles prevent this biomarker from being applied widely. On the o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Huiyuan, Li, Xinyi, Li, Wenbin, Zheng, Huyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345002/
https://www.ncbi.nlm.nih.gov/pubmed/25890369
http://dx.doi.org/10.1186/s12967-015-0435-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345002/
https://www.ncbi.nlm.nih.gov/pubmed/25890369
http://dx.doi.org/10.1186/s12967-015-0435-y

Ejemplares similares